Federal Circuit Affirms ITC Ruling: Wuhan Healthgen’s Heat Shock Protein Patents Held Unpatentable

In a significant decision for biotechnology patent practitioners, the U.S. Court of Appeals for the Federal Circuit affirmed the International Trade Commission’s finding that two heat shock protein patents held by Wuhan Healthgen Biotechnology Corp. were unpatentable. Case No. 23-1389, filed January 13, 2023, and closed February 7, 2025, after 756 days of litigation, represents a consequential outcome at the intersection of recombinant protein technology, ITC proceedings, and Federal Circuit patent validity jurisprudence.

The case centered on U.S. Patent Nos. 8,609,416 and 10,618,951, both directed to methods and compositions comprising heat shock proteins — a commercially significant class of biologics with applications in immunotherapy, vaccine adjuvants, and protein expression systems. For patent attorneys, IP professionals, and R&D teams operating in the biotechnology space, this affirmance underscores persistent risks in prosecuting and asserting patents in crowded therapeutic protein technology areas.

Case Overview

The Parties

Patents at Issue

This landmark case involved two heat shock protein patents covering methods and compositions, critical to cellular stress response and valuable as vaccine adjuvants and immunotherapy agents:

• • U.S. Patent No. 8,609,416 — Methods and compositions relating to heat shock proteins.
• • U.S. Patent No. 10,618,951 — A continuation-family patent similarly directed to heat shock protein compositions and methods.

Legal Representation

Plaintiff (Wuhan Healthgen) was represented by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP — with attorneys Elizabeth Niemeyer, Erik R. Puknys, J. Michael Jakes, Jason Lee Romrell, Michael Kudravetz, and Ryan Valentine McDonnell leading the appellate effort.

Defendant (ITC) was represented by Dominic L. Bianchi, Ronald Traud, and Wayne W. Herrington from the Commission’s own legal staff.

Litigation Timeline & Procedural History

The appeal originated from an ITC Section 337 investigation — a venue known for accelerated timelines relative to district court litigation. Wuhan Healthgen escalated the ITC’s adverse patentability determination to the Court of Appeals for the Federal Circuit, the exclusive appellate forum for patent-related appeals from the ITC.

The 756-day appellate duration reflects the Federal Circuit’s typical briefing and argument schedule for complex patent validity questions involving biotechnology. No chief judge assignment data was disclosed in the case record. The District of Columbia jurisdiction aligns with standard Federal Circuit sitting location, and no procedural anomalies suggesting emergency motions or extraordinary delays are indicated in the available case data.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a definitive order: AFFIRMED. The ITC’s finding that the patents-in-suit — U.S. Patent Nos. 8,609,416 and 10,618,951 — were unpatentable was upheld in full. The basis of termination is recorded as Unpatentable, confirming the invalidity/cancellation determination stood on appeal. No damages award is applicable given the nature of ITC invalidity proceedings; specific injunctive relief terms were not separately disclosed in the appellate record.

Verdict Cause Analysis

The verdict cause is identified as Patentability, under the broader category of Invalidity/Cancellation Action. While the Federal Circuit’s specific written opinion details are not fully reproduced in the case record, the unpatentability finding in heat shock protein cases typically implicates one or more of the following doctrines:

• Obviousness under 35 U.S.C. § 103: Heat shock proteins have been extensively studied since the 1960s–1980s, with a robust prior art landscape.
• Lack of Written Description or Enablement under 35 U.S.C. § 112: Biotechnology patents, particularly with broad functional claims over protein classes, face heightened scrutiny post-*Amgen v. Sanofi* (2023).
• Anticipation under 35 U.S.C. § 102: Prior art anticipation based on earlier published methods or compositions remains a viable invalidity ground.

The Federal Circuit’s affirmance signals agreement with the ITC’s underlying legal and factual analysis — a deferential standard applied to agency findings of fact, though claim construction and statutory interpretation receive de novo review.

Legal Significance

This decision carries meaningful precedential weight for:

• ITC Section 337 proceedings involving biotechnology patents — affirming the Commission’s authority and analytical rigor.
• Heat shock protein and molecular chaperone patent portfolios — signaling that broad claims in this technology space remain vulnerable.
• Federal Circuit deference standards — the affirmance suggests alignment between the ITC’s legal framework and Federal Circuit doctrine.

Strategic Takeaways

For Patent Holders:

• Invest heavily in prosecution-stage prior art searches for HSP and biologic compositions; a crowded art field demands narrowly tailored, well-supported claims.
• Continuation strategies provide portfolio depth but do not insulate against validity challenges if base claims are vulnerable.
• ITC is a powerful but high-risk forum — invalidity findings there carry appellate consequences.

For Accused Infringers and Defendants:

• ITC proceedings offer an efficient forum to resolve validity disputes on imported biotech products.
• An unpatentability finding eliminates the threat of exclusion orders.

For R&D Teams:

• Freedom-to-operate analyses in the heat shock protein and molecular chaperone space should account for the reduced enforceability of broad claims.
• Monitor the Federal Circuit docket for the published opinion in Case No. 23-1389 for specific claim language the court found unpatentable.

Industry & Competitive Implications

The biotech sector’s heat shock protein market — spanning oncology immunotherapy, infectious disease vaccines, and recombinant protein manufacturing — represents significant commercial stakes. Wuhan Healthgen’s defeat at the Federal Circuit removes a potential patent barrier affecting imported HSP-based products and compositions, with implications for competitors, licensees, and manufacturers operating in U.S. markets.

For companies like Agenus, StressMarq Biosciences, and academic-spinout HSP therapeutic developers, this decision may reduce licensing pressure tied to the Healthgen patent family. It also reflects a broader pattern: Chinese biotechnology firms asserting ITC actions to protect U.S. market positions face the same rigorous validity scrutiny as domestic patentees — a strategically important parity observation for international IP portfolio planning.

From a licensing perspective, the unpatentability finding renders these specific patents unenforceable, effectively ending any royalty-bearing licensing program built around U.S. Patent Nos. 8,609,416 and 10,618,951. Companies holding similar HSP patent families should proactively audit claim strength against the prior art landscape illuminated by this proceeding.

FAQ

What patents were involved in Wuhan Healthgen v. ITC?

U.S. Patent Nos. 8,609,416 (App. No. 12/972,112) and 10,618,951 (App. No. 15/188,478), both directed to methods and compositions comprising heat shock proteins.

What was the basis for the unpatentability finding?

The ITC found the patents unpatentable under an invalidity/cancellation action; the Federal Circuit affirmed. Specific grounds (obviousness, anticipation, or § 112) are detailed in the Federal Circuit’s written opinion for Case No. 23-1389.

How does this ruling affect heat shock protein patent litigation?

It signals that broad HSP patents face serious validity risks in ITC proceedings and Federal Circuit review, providing persuasive authority for defendants in related cases and FTO analyses.

*🔗 Research Resources: USPTO Patent Center | Federal Circuit Opinions | ITC Section 337 Investigations*